The purpose of this study was to evaluate if the tumor load, as determined by a real-time quantitative PCR (RQ-PCR) assay, correlated with the clinical course of follicular lymphoma patients after stem cell transplantation (SCT). Cryopreserved bone marrow and/or peripheral blood samples obtained at different time intervals after SCT from 11 patients (seven allogeneic, T-cell depleted/four autologous) were tested for tumor load, as defined by t(14;18) positive cells/total cells, using RQ-PCR. None of the six patients who remained in remission had samples with a tumor load 40.01% after SCT, although fluctuating tumor loads of p0.01% were observed in three of these patients. In contrast, four of the five patients (three allogeneic/two autologous) with relapsed/progressive disease had increasing tumor loads of 40.01% after SCT (0/6 vs 4/5, Po0.02, Fisher's exact). Our results suggest that RQ-PCR measurable tumor load 40.01% after SCT may correlate with relapsed/progressive disease. Prospective studies with greater numbers of cases are indicated to better determine the critical tumor load that predicts poor outcome after SCT with RQ-PCR.
tumor load; quantitative PCR; clinical course Stem cell transplantation (SCT), allogeneic or autologous, holds promise for improving the survival of follicular lymphoma (FL) patients. [1] [2] [3] [4] [5] FL is one of the most frequent subtypes of malignant lymphoma in Western countries and accounts for approximately 25% of all adult non-Hodgkin's lymphoma. 6 However, despite the intensive conditioning regimen and possible graft-versus-lymphoma (GvL) effect of allogeneic SCT, some patients (16-38%) still have relapse or progression of disease after allogeneic SCT. 1, 2 The relapse rate is even higher in patients receiving autologous SCT at about 58% at 8 years post-SCT. 3 Laboratory methods that can predict which patients are at risk of clinical relapse/progression after SCT are potentially valuable to improve the outcomes of SCT. The best example is the application of quantitative RT-PCR to measure BCR-ABL fusion transcripts as a marker of tumor load in chronic myeloid leukemia (CML). [7] [8] [9] In patients with CML, rising or persistently high levels of tumor load, BCR-ABL to ABL ratio of 40.02% or 4100 BCR-ABL transcripts/mg RNA, in two sequential specimens more than 4 months following SCT are predictive of overt clinical relapse. 7 Furthermore, treating CML patients before there is overt clinical relapse of disease with donor lymphocyte infusion (DLI) has improved the survival of CML patients after SCT. 8 Unlike CML, studies to determine the clinical significance of the tumor load in FL after SCT are very limited. 9 Hirt et al 10 have recently reported that relapses are associated with increasing numbers of circulating t(14;18)-positive cells, while continuous complete clinical remissions are associated with stable t(14;18)-positive cell counts in seven patients following autologous SCT. Mandigers et al 11 reported that levels of tumor load correlated with remission after using DLI to treat the relapse of FL following allogeneic SCT in one patient.
The main purpose of the current study was to evaluate if the level of tumor load correlated with the clinical course in 11 patients with FL after SCT (seven allogeneic, T-cell depleted and four autologous). We measured the level of tumor load, t(14;18)-positive cells/total mononuclear cells, using a real-time quantitative PCR (RQ-PCR) assay.
Materials and methods

Patients and samples
We retrospectively studied 11 FL patients who underwent T-cell-depleted allogeneic SCT or autologous SCT at the Medical College of Wisconsin from February 1990 to November 1999. The T-cell depletion was performed using the protocol reported previously. 12 Allogeneic patients in this study received grafts with a 2.270.7 log depletion of T cells, resulting in T-cell doses/kg ranging from 4.15 Â 10 4 to 3.6 Â 10
5
. These patients were studied because cryopreserved bone marrow (BM) and/or peripheral blood (PB) mononuclear cells of these patients collected before SCT were positive for t(14;18) using the RQ-PCR assay described below. A total of 70 samples obtained at various time intervals after SCT from these 11 patients was further tested for tumor load using the RQ-PCR assay.
Demographic data and the clinical course of the 11 patients are summarized in Table 1 . These patients received SCT for relapsed/refractory FL. All patients except cases 4, 9, and 10 ( Table 1) were conditioned with total body irradiation, AraC, and Cytoxan. Case #4 was conditioned with BEAM, Case #9 with etoposide, cisplatin, cyclophosphamide, and carmustine and Case #10 with VP-16, Cytoxan, cisplatin, and carmustine. The median length of follow-up in these patients post-SCT was 76 months (85 months for survivors), ranging from 7 months to 152 months (45 to 152 months for survivors). The end point of follow-up was either the date of the last visit or the date of death up to December 2002. This study was approved by the Institutional Review Board of Medical College of Wisconsin.
RQ-PCR assay
This RQ-PCR assay was developed to detect and quantitate the cells carrying t(14;18) at the major breakpoint region (MBR). Briefly, total cellular DNA from the cell line, SUDHL-6 containing t(14; 18)(q32;q21), normal human placenta, and patients' samples were prepared using Puregene DNA Isolation Kit (Gentra Systems, Minneapolis, MN, USA). The standard curve for quantitating the tumor load, the ratio of t(14:18)+ cells/total cells, was established by standardized samples, with the different ratios of SUDHL-6 DNA/total DNA ( ¼ SUDHL-6 DNA+placen-ta DNA). A total of four standardized samples with tumor loads of 10% (one tumor cell in 10 total cell), 1% (one in 100), 0.1% (one in 1000), and 0.01% (one in 10 000), respectively, was made for establishing a standard curve. One additional standardized sample, with a tumor load of 0.0025% (one tumor cell in 40 000 total cells), was prepared to test the sensitivity of the assay.
PCR was performed in a 20 ml volume containing 250 ng DNA from each standardized sample or patient samples, The PCR amplification and quantitation of PCR products were performed on a LightCyclert (Roche Diagnostics). After 10 min at 951C to activate Amplitaq Gold, the following reaction was carried out: five cycles of denaturation at 941C for 0 s, annealing at 671C for 5 s and extension at 741C for 15 s, followed by 45 cycles of denaturation at 941C for 0 s, annealing at 631C for 5 s, and extension at 741C for 15 s. The tumor loads of each patient sample were assessed using the standard curve established by the standardized samples ( Figure 1 ).
All the patients' samples were tested in duplicate initially. If both runs were negative, an additional two runs were performed to reach the sensitivity of detecting one neoplastic cell in 160K normal cells (0.0006%). The tumor load was calculated as the average of two or four runs.
For each patient sample, the b-globin gene was amplified separately using another RQ-PCR assay similar to the one described above with primers (5
0 ), and 5 0 end LCRed 640-labeled (5 0 -gagaccattgtggcagtgat-3 0 ) probes targeting bglobin gene. This was to ensure that all samples contained similar amounts of DNA and were free of PCR inhibitors.
Results
The RQ-PCR assay showed the sensitivity of detecting a single cell carrying t(14;18) in the background of 40 000 normal cells (ie a tumor load of 0.0025%). The linear measuring range of the standard curve of quantitation of the assay was between tumor loads of 0.01 and 10% (Figure 1 ). For samples with a tumor load less than 0.01%, the tumor load was estimated based on the standard curve with the understanding that the measurement might not be accurate. Additionally, an interassay (eight experiments using standardized samples with tumor loads of 10, 1, 0.1, and 0.01%) coefficient of variation (CV) of p10.6% and an intraassay (six measurements of identical samples) CV of p6.9% were achieved for reproducibility. The CV increased significantly when the tumor load was below 0.01%.
Out of 11 patients, 10 achieved a complete clinical remission after SCT as determined by physical, CT scan, and/or bone marrow examination (Table 1) . Six (two autologous and four allogeneic) of these 10 patients remained in complete clinical remission with a median follow-up length of 132 months (ranging from 55 to 152 months) after SCT. None of these six patients received any further treatment, including DLI or other immunomanipulation, after SCT. The remaining four patients (two autologous and two allogeneic) had relapse at 5, 13, 14, and 36 months, respectively (cases #11, #9, #10, and #8, respectively). Three relapsed patients ultimately died of . 17 The results show that the log of the tumor load (in percentage) is inversely correlated to the 'threshold cycle number', the number of the PCR cycle at which the fluorescence intensity generated by products (due to FRET) becomes greater than the background intensity. 17 Tumor load may correlate with clinical course C-C Chang et al progressive disease (cases #9, 10, and, 11) and one attained complete clinical remission after DLI (case #8). Only one allogeneic recipient did not achieve a complete remission after SCT. She died of progressive disease 11 months after SCT (case #7). Using this RQ-PCR assay, none of the six patients who remained in complete clinical remission had any samples reaching a tumor load of 0.01% after SCT (Figure 2 ). Three (cases #1, #2, and #6) of the six patients in complete clinical remission showed fluctuating tumor loads of o0.01%, while the other three patients had no detectable tumor load after SCT (Figure 2 ). In contrast, four of the five patients who had relapsed/progressive disease had one or more samples showing tumor load 40.01% (ranging from 0.012 to 5.79%, Figure 3 ) (0/6 vs 4/5, Po0.02, Fisher's exact). Furthermore, clinical relapse/progression was accompanied by a tumor load of 40.1% in four patients (cases #7, #8, #9, and #10, Figure 3 ). In two patients (cases #9 and #10), CT scan/bone marrow/physical examination failed to show any signs of relapsed/progressive disease at the time of tumor load 40.01%. The time interval between the samples showing tumor load 40.01% and clinical relapse in these two patients were 56 and 359 days, respectively (Figure 3) . In one patient, clinical relapse was associated with at least 10-fold higher level of tumor load than the initial sample showing tumor load 40.01% (case #9, Figure 3 ).
None of the seven patients who received allogeneic SCT developed acute GVHD of grade III or higher (Table 1) . Five patients had extensive chronic GVHD, one had limited chronic GVHD, and one had no chronic GVHD. There was, however, no apparent difference in the degree of acute or chronic GVHD between patients with relapsed/ progressive disease (two of three acute GVHD and two of three chronic GVHD) and those without (three of four acute GVHD and four of four chronic GVHD).
Discussion
Our results suggest that the tumor load measured by the RQ-PCR assay correlates with clinical course of patients with follicular lymphoma after SCT. The patients with tumor loads constantly below 0.01% had enduring remission of disease, while those with tumor load of 40.01% were at risk of relapse/progression. Furthermore, clinical relapse/progression after SCT was associated with a tumor load 40.1%. Our results in patients with autologous SCT agree with those reported by Hirt et al. 10 Using a different quantitative PCR assay, they observed that patients with continuous complete remission had circulating t(14;18)-positive cells at the levels of o0.01%. In one of their two patients, the relapse was accompanied by a logarithmic increase of t(14;18)-positive cells over a tumor load of Dead at 7 mos Disease AU: autologous SCT, Chlor: chlorambucil, CR: complete remission, Dx: diagnosis, mos: months, GVHD: graft-versus-host-disease. Hu: hydroxyurea, NA: not applicable, PR: partial remission, RM: related matched, TD: T-cell depleted, XRT: radiation therapy. *Developed posttransplant lymphoproliferative disorder (PTLD) 60 months post-SCT. The PTLD lesion showed evidence of EBV infection and was negative for t(14;18) using the same PCR assay. #Received allogeneic SCT at 48 months after autologous SCT secondary to MDS.
0.01%. There are no data available in the literature to be compared with our findings for patients with allogeneic SCT.
The correlation between the levels of tumor load and clinical course in FL recipients of T-cell-replete SCT requires further investigation, as all of the allogeneic recipients in our study received T-cell-depleted SCT. Tcell-depleted SCT may have the disadvantage of weaker GVL effect associated with the desired less-severe GVHD. However, there were no apparent differences in the degree of acute or chronic GVHD between patients with relapsed/ progressive disease and those with stable remission in this small series of patients.
Our findings further indicate that long-term monitoring of tumor load with RQ-PCR may be necessary for FL patients receiving SCT, since tumor load may gradually increase following a transient decrease after SCT (Figure 2 ). One patient (case #8) demonstrated an increase in tumor load associated with clinical relapse 1081 days after SCT. This observation is in agreement with van Besien et al 2 who reported that, although uncommon, disease relapse may occur 2 years or more after allogeneic SCT. Additionally, consistent with previous studies, we showed that some patients may have fluctuating low levels (o0.01%) of tumor loads after SCT without clinical relapse. 3, 10, [13] [14] [15] [16] These patients, however, may require close follow-up to evaluate if the tumor load is stable, decreasing, or increasing over time. Further studies are needed to determine the optimal length and interval of monitoring tumor load.
In the current study, we identified two patients from whom samples with tumor load 40.01% were obtained up to 359 days prior to clinical relapse. In these two patients, there was no evidence of clinical relapse by either physical, bone marrow, or CT scan examination at the time the samples were obtained. However, gallium scan, which may be more sensitive than CT scan, was not performed in these patients. Our findings agree with the observation by Mandigers et al. 11 They observed a patient whose tumor load remained over 0.01% after allogeneic SCT, even though he was in complete clinical remission. This patient below tumor loads of 0.0006% (sensitivity limit of the assay with same samples run in quadruplicate). The data points below this level (0.0006%) should be regarded as the same although they are shown differently for illustration purpose. The case number designated is identical to that of Table 1 . Table 1. eventually had clinical relapse 2 years later. Furthermore, it is important to note that the tumor load increased at least one log when overt clinical relapse occurred in one of our patients and the case reported by Mandigers. Taken together, our results suggest the tumor load measured by the RQ-PCR assay may predict the clinical course of FL patients receiving SCT. The current study is, however, limited by its retrospective nature without planned sampling of patients at regular intervals after SCT. Prospective studies with a larger sample size and regular sampling are indicated to evaluate if a critical level of tumor load, beyond which clinical relapse is inevitable, can be determined. If so, pre-emptively treating patients at this critical level, but without overt clinical relapse, can be considered. This approach may allow treatment at a stage when tumor burden is relatively low, resulting in improved outcome. This may be particularly important for FL patients undergoing allografts, as lower dose DLI may be used at this stage to generate an efficacious GVL effect while avoiding severe GVHD, as shown in CML patients. 8 
